-
2023-503170-20-00
1
Advanced solid tumors
-
2023-505334-10-00
7
Unresectable, Locally Advanced, or Metastatic Solid Tumors
-
2023-505380-36-00
5
Patients with stage I, II, III hormone-receptor positive (HR+) breast
-
2023-506014-47-00
9
Resected (R0 or R1) pancreatic ductal adenocarcinoma
-
2024-515603-19-00
4
Localized digestive Neuroendocrine Carcinomas
-
2024-519922-19-00
4
Neuroendocrine carcinoma of gastro-enteropancreatic or unknown origin
-
2023-505380-36-01
5
Patients with stage I, II, III hormone-receptor positive (HR+) breast
-
2023-505469-95-00
10
Primary Sclerosing Cholangitis
-
2023-508476-11-00
1
Adenoid cystic carcinoma (ACC)
-
2023-508658-24-00
4
type B3 thymoma and thymic carcinoma
-
2024-512195-35-00
5
Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-p
-
2024-513724-42-00
10
Medulloblastoma
-
2024-513889-19-00
5
Multiple Myeloma
-
2024-515306-61-00
6
Adults diagnosed with lower limbs erysipelas
-
2024-515603-19-01
4
Localized digestive Neuroendocrine Carcinomas
-
2024-516115-24-00
9
High risk relapsed neuroblastoma (relapsed or progressed after being d
-
2024-516570-30-00
4
Relapsed/refractory T-cell Acute Lymphoblastic Leukemia
-
2024-517133-40-00
5
newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
-
2024-517339-30-00
7
Advanced Solid Tumors
-
2024-518326-32-00
7
Patients with advanced solid malignancies that have progressed followi
-
2024-518871-74-00
4
Locally Advanced or Metastatic Solid Tumours that harbour MET Amplific
-
2024-519504-27-00
5
Relapsed Refractory Multiple Myeloma
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2024-519753-11-00
4
Resectable borderline pancreatic adenocarcinoma